Aptose Reports Results for the Fourth Quarter and Full Year 2023
March 26, 2024 16:01 ET
|
Aptose Biosciences, Inc.
Aptose Reports Results for the Fourth Quarter and Full Year 2023
Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024
March 18, 2024 16:30 ET
|
Aptose Biosciences, Inc.
Aptose to Report Fourth Quarter and Year End 2023 Financial Results and
Provide Corporate Update on Tuesday, March 26, 2024
Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option
January 31, 2024 16:01 ET
|
Aptose Biosciences, Inc.
Aptose closes previously announced public offering and private placement
Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical
January 26, 2024 08:00 ET
|
Aptose Biosciences, Inc.
Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical
Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting
December 09, 2023 18:30 ET
|
Aptose Biosciences, Inc.
ASH Oral Presentation: Complete Response Data from the Ongoing APTIVATE Phase 1/2 Study of Tuspetinib (TUS) in R/R AML Patients
Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role
November 30, 2023 16:59 ET
|
Aptose Biosciences, Inc.
Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role
Aptose Reports Results for the Third Quarter 2023
November 09, 2023 16:00 ET
|
Aptose Biosciences, Inc.
Aptose Reports Results for the Third Quarter 2023
• TUS/VEN Therapy Active in R/R VEN Failure AML Patients – Guides Toward Accelerated Approval Path
Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting
November 02, 2023 09:00 ET
|
Aptose Biosciences, Inc.
Dr. Naval Daver from MD Anderson Cancer Center will present data from Aptose’s AML Drug Candidate Tuspetinib in an Oral Presentation at ASH 2023
Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib
October 30, 2023 09:15 ET
|
Aptose Biosciences, Inc.
Aptose Presents Latest Available Data on AML Drug Tuspetinib - 48% ORR with TUS/VEN in Heavily Pre-treated R/R AML Patients
Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023
October 26, 2023 07:11 ET
|
Aptose Biosciences, Inc.
Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023